Akums Launches Oral Suspension of Hydroxyurea Effective in the Treatment of Sickle Cell Disease and Driving the Oral Syringes Market

Akums Drugs and Pharmaceuticals announced the launch of an oral suspension that is stable at room temperature and received regulatory approval from the Drug Controller General of India. This formulation of hydroxyurea does not need any cold storage and it is an easily accessible and readily available product to treat sickle cell diseased patients. With the guidance of Dr. V. K. Paul, a member of NITI Aayog, and under the team leadership of Home Minister, Mansukh Mandviya, this joint initiative was taken by Akums. This new product coexists with oral syringes that enable the precise administration of dosage for adults, pediatrics, and adolescents.

Oral Syringes Market Size

According to Precedence Research’s Report, the global oral syringes market was USD 1.62 billion in 2023 and is estimated to reach around USD 3.02 billion by 2033, expanding at a CAGR of 6.43% from 2024 to 2033.

In August 2024, the Adelphi Partner elm-plastic introduced a 1.5 ml syringe to its short-form oral dosing syringe range. The short-form oral pipettes are available in 1.5 ml, 3 ml, 12 ml, 15 ml, and 25 ml enabling precise and accurate dosage administration in patients. For the year 2022-2023, 5,453 drugs and pharmaceuticals and 2,628 Medtech activities were reported as per the annual report 22-23 of the Government of India Ministry of Chemicals and Fertilizers, Department of Pharmaceuticals.

Along with oral syringes, there is an increased demand for other medical equipment like surgical instruments, consumables and disposables, implants, electronic equipment, etc. According to PubMed Publication, 87.5% of children were familiar with oral syringes due to increased medical needs and benefits in the accurate dosage measurement, thereby driving the growth of the oral syringes market.

As per the statement, the growing prevalence of chronic diseases such as diabetes, cancer, and cardiovascular disorders has led to an increase in the prescription of liquid medications. According to a report by the World Health Organization (WHO), approximately 422 million people worldwide were living with diabetes in 2014, with that number expected to rise substantially by 2030. This increase translates into a higher demand for liquid formulations, subsequently fueling the oral syringes market.

The Growth of the Pharma Sector at Current Prices, 2017-2022

Financial Year	Turnover (Rs. In Crore)	Growth Rate
2017-2018	2,26,423	3.03
2018-2019	2,58,534	14.18
2019-2020	2,89,998	12.17
2020-2021	3,28,054	13.12
2021-2022	3,44,125	4.89

Research indicates that the investment in R&D for oral syringe development was approximately $50 million in 2022 and is projected to reach $70 million by 2024. This uptick in investment reflects the industry’s commitment to enhancing the safety and efficacy of oral drug delivery systems. In 2022, an estimated 75% of oral syringes produced met these new regulatory requirements, indicating a significant shift toward enhanced quality assurance.

The focus on quality, safety, and effectiveness will remain paramount, ensuring that oral syringes play a critical role in the future of medication administration. With these developments, the oral syringes market is set for sustained growth, promising improved patient experiences and outcomes.